Treatment of Heart Failure with Spironolactone — Trial and Tribulations
作者： John J.V. McMurray , Eileen O'Meara
DOI: 10.1056/NEJMP048144
关键词: Renal function 、 Spironolactone 、 Heart failure 、 Surgery 、 Pharmacotherapy 、 Heart disease 、 Internal medicine 、 Clinical trial 、 Medicine 、 MEDLINE
摘要: After the release of results RALES trial, there was a striking increase in hospital admissions and deaths related to hyerkalemia. Dr. John McMurray Eileen O'Meara explain that ...
sci-hub.se 参考文章(3)
David N. Juurlink, Muhammad M. Mamdani, Douglas S. Lee, Alexander Kopp, Peter C. Austin, Andreas Laupacis, Donald A. Redelmeier, Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study The New England Journal of Medicine. ,vol. 351, pp. 543- 551 ,(2004) , 10.1056/NEJMOA040135
Bertram Pitt, Faiez Zannad, Willem J. Remme, Robert Cody, Alain Castaigne, Alfonso Perez, Jolie Palensky, Janet Wittes, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine. ,vol. 341, pp. 709- 717 ,(1999) , 10.1056/NEJM199909023411001
Effectiveness of Spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]) American Journal of Cardiology. ,vol. 78, pp. 902- 907 ,(1996) , 10.1016/S0002-9149(96)00465-1